BioCentury | Oct 6, 2017
Clinical News

Motif's iclaprim meets in second Phase III for ABSSSIs

...iclaprim to treat complicated skin and skin structure infections (cSSSI) when the compound belonged to Arpida...
...acquired iclaprim in 2015 through a merger with Nuprim Inc., which was launched by former Arpida...
BioCentury | Apr 27, 2017
Clinical News

Iclaprim: Ph III REVIVE-1 data

...iclaprim to treat complicated skin and skin structure infections (cSSSI) when the compound belonged to Arpida...
...acquired iclaprim in 2015 through a merger with Nuprim Inc., which was launched by former Arpida...
BioCentury | Dec 1, 2016
Clinical News

SER150: Ph IIa ongoing

...to the product from Evolva (see BioCentury, Oct. 14, 2013 & Jan. 13, 2014 ). Evolva Holding S.A....
...proteinuria and measurement of urinary thromboxane Status: Phase IIa ongoing Milestone: Phase IIa data (01/2017) Alicia Parker EV-077 SER150 Evolva Holding S.A. Serodus...
BioCentury | Nov 18, 2016
Company News

Management tracks

...ApS (Copenhagen, Denmark) named Jakob Dynnes Hansen CFO, replacing Henrik Moltke. Hansen was CFO of Evolva Holding S.A....
BioCentury | Mar 7, 2016
Clinical News

Iclaprim: Phase III started

...iclaprim to treat complicated skin and skin structure infections (cSSSIs) when the compound belonged to Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Sep 14, 2015
Clinical News

Iclaprim regulatory update

...iclaprim to treat complicated skin and skin structure infections (cSSSIs) when the compound belonged to Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Sep 7, 2015
Clinical News

Motif Bio preclinical data

...treat complicated skin and skin structure infections (cSSSIs), when the compound belonged to Arpida Ltd. Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Aug 3, 2015
Clinical News

Iclaprim regulatory update

...iclaprim to treat complicated skin and skin structure infections (cSSSIs), when the compound belonged to Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Jul 18, 2015
Company News

QIDP for Motif's iclaprim triggers L22M placing

...iclaprim to treat complicated skin and skin structure infections (cSSSIs), when the compound belonged to Arpida...
...from EMA's CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | May 18, 2015
Company News

Evolva Holding, Emergent BioSolutions deal

...Emergent acquired Evolva’s EV-035 antibiotic portfolio, including preclinical melioidosis candidate GC-072 . The U.S. Department of...
...Defense Threat Reduction Agency is funding preclinical development of GC-072 under a 2014 contract with Evolva...
...government approval of the contract’s transfer to Emergent triggered a $4 million upfront payment to Evolva...
Items per page:
1 - 10 of 209
BioCentury | Oct 6, 2017
Clinical News

Motif's iclaprim meets in second Phase III for ABSSSIs

...iclaprim to treat complicated skin and skin structure infections (cSSSI) when the compound belonged to Arpida...
...acquired iclaprim in 2015 through a merger with Nuprim Inc., which was launched by former Arpida...
BioCentury | Apr 27, 2017
Clinical News

Iclaprim: Ph III REVIVE-1 data

...iclaprim to treat complicated skin and skin structure infections (cSSSI) when the compound belonged to Arpida...
...acquired iclaprim in 2015 through a merger with Nuprim Inc., which was launched by former Arpida...
BioCentury | Dec 1, 2016
Clinical News

SER150: Ph IIa ongoing

...to the product from Evolva (see BioCentury, Oct. 14, 2013 & Jan. 13, 2014 ). Evolva Holding S.A....
...proteinuria and measurement of urinary thromboxane Status: Phase IIa ongoing Milestone: Phase IIa data (01/2017) Alicia Parker EV-077 SER150 Evolva Holding S.A. Serodus...
BioCentury | Nov 18, 2016
Company News

Management tracks

...ApS (Copenhagen, Denmark) named Jakob Dynnes Hansen CFO, replacing Henrik Moltke. Hansen was CFO of Evolva Holding S.A....
BioCentury | Mar 7, 2016
Clinical News

Iclaprim: Phase III started

...iclaprim to treat complicated skin and skin structure infections (cSSSIs) when the compound belonged to Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Sep 14, 2015
Clinical News

Iclaprim regulatory update

...iclaprim to treat complicated skin and skin structure infections (cSSSIs) when the compound belonged to Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Sep 7, 2015
Clinical News

Motif Bio preclinical data

...treat complicated skin and skin structure infections (cSSSIs), when the compound belonged to Arpida Ltd. Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Aug 3, 2015
Clinical News

Iclaprim regulatory update

...iclaprim to treat complicated skin and skin structure infections (cSSSIs), when the compound belonged to Arpida...
...from EMA’s CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | Jul 18, 2015
Company News

QIDP for Motif's iclaprim triggers L22M placing

...iclaprim to treat complicated skin and skin structure infections (cSSSIs), when the compound belonged to Arpida...
...from EMA's CHMP. Motif acquired iclaprim in April through a merger with Nuprim Inc. Former Arpida...
BioCentury | May 18, 2015
Company News

Evolva Holding, Emergent BioSolutions deal

...Emergent acquired Evolva’s EV-035 antibiotic portfolio, including preclinical melioidosis candidate GC-072 . The U.S. Department of...
...Defense Threat Reduction Agency is funding preclinical development of GC-072 under a 2014 contract with Evolva...
...government approval of the contract’s transfer to Emergent triggered a $4 million upfront payment to Evolva...
Items per page:
1 - 10 of 209